Plain-English translation of NCT07375953 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that dissolves blood clots in the brain during stroke. If you receive an initial dose of within 3 hours of your stroke but don't show enough improvement after 1 hour, researchers will study whether giving you a second dose of the medication might help restore blood flow and reduce stroke damage.
Standard clot-busting treatments don't work well enough for some stroke patients—they still have blocked blood vessels even after the first dose. This study is exploring whether a second dose of this medication could help patients who aren't improving, potentially saving brain tissue and improving recovery.
You likely qualify if…
You likely don't qualify if…
If you qualify and have a stroke, you'll receive your first dose of the medication within 3 hours of stroke onset. One hour later, doctors will check if you've improved; if not, you may receive a second dose as part of this study. Researchers will monitor you closely and use brain imaging to track blood vessel opening and your recovery over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China